Cullinan Therapeutics (CGEM) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cullinan Therapeutics (CGEM) has outperformed Sana Biotechnology (SANA) over the past year, gaining 165.4% versus a loss of 34.0%. Over five years, CGEM leads with a -37.5% price change compared with -86.9% for SANA. Cullinan Therapeutics is the larger company by market cap ($950.1 million vs $835.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | SANA |
|---|---|---|
| Share price | $15.46 | $2.79 |
| Market cap | $950.14M | $835.22M |
| 1-day change | -1.09% | +2.57% |
| YTD return | +51.01% | -33.17% |
| 1-year return | +165.37% | -33.98% |
| 5-year return | -37.48% | -86.92% |
| EPS (TTM) | $-3.11 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $6.55 |
| 52-week low | $6.50 | $2.61 |
| Distance from 52-week high | -33.33% | -57.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +116.36% | +202.15% |
| Average volume | 871.08K | 3.10M |
| Shares outstanding | 61.46M | 299.36M |
| Employees | 109 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEM has outperformed SANA by 199.3 percentage points over the past year.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
CGEM vs SANA FAQ
Which is bigger, Cullinan Therapeutics or Sana Biotechnology?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $950.14M compared with $835.22M for Sana Biotechnology (SANA).
Which stock has performed better over the past year, CGEM or SANA?
CGEM returned +165.37% over the past 12 months, compared with -33.98% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Sana Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.